Product image of Norditropin Flexpro (Somatropin) supplied by GNH India

Norditropin Flexpro

Active Ingredient:
Somatropin
Origin:
EU

Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a Human growth hormone presented as a solution for injection for subcutaneous use. It treats growth hormone deficiency in children and adults and is indicated for several growth‑related disorders. It is used under medical supervision to promote linear growth in pediatric patients and to improve body composition, bone density, and metabolic parameters in adult patients with confirmed deficiency.

GNH India supplies Norditropin Flexpro as a licensed, GDP‑compliant supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novo Nordisk B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Norditropin Flexpro, a recombinant human growth hormone, is used to address conditions characterized by growth hormone deficiency or impaired growth.

  • Growth hormone deficiency in children: increases growth velocity and helps achieve normal adult height.
  • Growth hormone deficiency in adults: improves body composition, bone density, and metabolic health.
  • Turner syndrome: promotes linear growth and improves final height in affected females.
  • Chronic renal insufficiency: supports growth in pediatric patients with renal‑related growth failure.
  • Prader‑Willi syndrome: enhances growth and may improve body composition in children.
  • Short stature associated with Noonan syndrome: stimulates growth to reduce height deficit.

How It Works

  • Somatropin binds to growth hormone receptors on target cells, activating the JAK2‑STAT5 signaling cascade. This stimulates hepatic synthesis of insulin‑like growth factor‑1 (IGF‑1) and modulates downstream anabolic processes, including protein synthesis, lipolysis, and bone growth. The increased IGF‑1 mediates many of the growth‑promoting and metabolic effects observed with therapy. The hormone also influences carbohydrate metabolism and supports immune function, contributing to overall physiological homeostasis during treatment.

Side Effects

Somatropin therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Injection site pain or erythema.
  • Headache.
  • Joint or muscle aches.
  • Peripheral edema.

Serious or Rare Side Effects

  • Intracranial hypertension.
  • Slipped epiphysis (growth plate closure).
  • Hyperglycemia or new‑onset diabetes.
  • Severe allergic reaction (anaphylaxis).

Precautions & Warnings

When prescribing Norditropin Flexpro, clinicians should consider several safety measures.

  • Monitor glucose levels: patients with diabetes may experience altered glycemic control.
  • Assess thyroid function: hypothyroidism can blunt growth response.
  • Screen for intracranial hypertension: discontinue if symptoms develop.
  • Evaluate for malignancy: use with caution in patients with active cancer.
  • Avoid use in active proliferative retinopathy: may worsen condition.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Somatropin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

  • Concurrent high‑dose glucocorticoids: may reduce somatropin efficacy.
  • Insulin or oral hypoglycemics: increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Oral estrogen therapy: may alter IGF‑1 response.
  • Thyroid hormone replacement: requires dose adjustment of levothyroxine.
  • Anticonvulsants (e.g., carbamazepine): may increase somatropin clearance.

Frequently Asked Questions

Norditropin Flexpro is a recombinant human growth hormone indicated for treating growth hormone deficiency in children and adults, as well as for specific growth‑related conditions such as Turner syndrome, chronic renal insufficiency, Prader‑Willi syndrome, and short stature associated with Noonan syndrome.

Somatropin binds to growth hormone receptors on target cells, triggering the JAK2‑STAT5 pathway and stimulating the liver to produce insulin‑like growth factor‑1 (IGF‑1). The rise in IGF‑1 drives anabolic processes that promote linear growth, increase bone density, and improve body composition and metabolism.

The dose of Norditropin Flexpro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, diagnosis, and treatment goals, and adjusts it according to clinical response and laboratory monitoring.

Safety of somatropin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options, and necessary import documentation.

Norditropin Flexpro is a recombinant somatropin formulation similar in efficacy to other branded GH products such as Genotropin or Saizen. Differences may lie in device design, stability profile, and packaging, but the active molecule and clinical outcomes are comparable when dosed appropriately.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once in use, the solution can be kept at room temperature for a limited period as indicated in the product’s prescribing information.

Norditropin Flexpro is supplied as a sterile solution for subcutaneous injection. The dose is drawn into a disposable pen or syringe and injected into the fatty tissue of the abdomen, thigh, or upper arm, following the administration technique recommended by the prescriber.

Serious risks include intracranial hypertension, slipped epiphysis (premature closure of growth plates), hyperglycemia or new‑onset diabetes, and severe allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions, and therapy should be stopped if they occur.

Norditropin Flexpro is contraindicated in patients with active malignancy, acute critical illness, or known hypersensitivity to somatropin or any excipients. It should also be avoided in individuals with proliferative retinopathy or uncontrolled diabetes without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Somatropin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT